Boyer David W. 4

What Happened David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences (NBIX), disposed of 3,888 shares on May 26, 2026 in open-market transactions. The weighted average sale price was $156.64 per share, for total gross proceeds of roughly $609,023. The sales were executed by a broker under a Rule 10b5-1 trading plan adopted by Mr. Boyer on February 23, 2026.

Key Details

• Transaction date: 2026-05-26 (reported on Form 4 filed 2026-05-28).
• Shares sold: 3,888; weighted average price: $156.64; gross proceeds ≈ $609,023.
• Price range: sales occurred at prices between $155.81 and $157.62 (multiple trades).
• Ownership after transaction: not specified in the information provided in this summary (the filing should show "amount owned following" if reported).
• Notable footnotes:
  • F1: Sales were effected by a broker per a Rule 10b5-1 plan adopted 2026-02-23; issuer policy prevents amending the plan after adoption.
  • F2: Weighted average price disclosed; the filer can provide the number of shares sold at each price on request.
  • F3: The filer notes an aggregate of 106 shares were purchased on 2026-02-27 under the company’s 2018 ESPP (this may be reflected in ownership totals).
• Filing timeliness: Form 4 was filed two days after the transaction (appears timely).

Context This was a sale executed under a pre-established 10b5-1 trading plan, which generally indicates the trades were pre-planned rather than opportunistic. Sales are typically routine insider activity and do not necessarily reflect the insider’s current view of the company’s prospects. There was no option exercise, gift, or award reported in this transaction.